Clinical Trials Logo

Autoimmune Diseases clinical trials

View clinical trials related to Autoimmune Diseases.

Filter by:

NCT ID: NCT04039763 Recruiting - Diabetes Mellitus Clinical Trials

RT-CGM in Young Adults at Risk of DKA

YODA
Start date: September 3, 2020
Phase: N/A
Study type: Interventional

Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses. Hypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.

NCT ID: NCT04022655 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit

Start date: July 22, 2019
Phase:
Study type: Observational

Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, or anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, may affect multiple organ systems. Occasionally, patients deteriorate acutely requiring advanced care in an intensive care unit (ICU). In an ICU setting, mortality is estimated with scoring systems, such as APACHE or SAPSII. Since there are limited data available on their use in autoimmune diseases, with the current study, we aim to assess the usefulness of these ICU scores and analyze predictors of mortality in this particular group of patients.

NCT ID: NCT04015596 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

Start date: October 20, 2020
Phase: Phase 4
Study type: Interventional

This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children. To accomplish this goal, the investigators will conduct a double-blind, randomized, placebo-controlled trial of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID) in participants diagnosed with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). This research fills a gap in the empirical evidence base for the treatment of PANDAS, and will add to a growing literature of empirically-derived practices for PANDAS.

NCT ID: NCT04007939 Completed - Clinical trials for Cardiovascular Risk Factor

Personal Lifestyle Engine (PLX) - Personal Lifestyle Medicine Center (PLMC)

Start date: January 1, 2018
Phase:
Study type: Observational

It has been suggested that the best medicine should include four principles (4P) - Medicine should be personalized, predictive, preventative and participatory. Technology has provided the tools to collect data in ways not previously possible. Individuals can now collect information on their genome (including their genetic predisposition to tolerate medications and to respond to healthy lifestyle programs) that will modify their lifestyle and therapeutic choices. Beyond spot checks of vital signs and weight, individuals can now collect information on body composition, continuous monitoring of heart rate, blood pressure, and even blood sugar. Data on food consumption at a caloric, macronutrient and even micronutrient level can be collected. Standard medical histories and detailed physical examination findings and laboratory biomarkers can be correlated with this data. Collections of individual patient data will need to be managed through computer programs and smart phone applications that provide direct feedback about the influence of lifestyle on health, wellness and biomarkers. To this end, Metagenics is designing and is launching a smart phone application, Personal Lifestyle Engine (PLX), for individual use by patients and their healthcare providers. The statistical analysis of these data is the primary objective of this study.

NCT ID: NCT04005456 Completed - Clinical trials for Cardiovascular Risk Factor

Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design

LIFE-HOUSE
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease risk determinants. LIFE-HOUSE will utilize an innovative Tent-Umbrella-Bucket design. Participants will gather under the Tent of an all-inclusive 'N of 1' Case Series providing a shelter of Functional Medicine interventions against the storm of chronic disease. Under this Tent are a collection of Umbrellas where participants with similar clinical challenges are evaluated as clinically defined groups with loose guidelines for the planned interventions. Finally, participants standing under these Umbrellas may step into specific Buckets that gather individuals with nearly identical clinical presentations into more formally described prescriptive randomized arms for intervention. Individuals will be offered the opportunity to participate in all Umbrellas and Buckets for which they qualify. They may accept or reject participation in any Umbrella or Bucket and yet remain eligible for participation in the overall Tent.

NCT ID: NCT03956953 Completed - Autoimmune Diseases Clinical Trials

Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects

Start date: April 4, 2019
Phase: Phase 1
Study type: Interventional

Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.

NCT ID: NCT03953768 Recruiting - Epilepsy Clinical Trials

VNS Prospective Neuromodulation of Autonomic, Immune and Gastrointestinal Systems

VNSAIG
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of efficacy is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune, gastrointestinal and autonomic systems. The primary objective of this study is to characterize the pre- and post-operative bowel habits and gut microbiome of patients implanted with vagal nerve stimulator (VNS) for epilepsy. Secondary objectives of this study include: (1) to characterize the pre- and post-operative autonomic profile, (2) characterize the pre- and post-operative immune profile, and (3) to elucidate whether gut microbiota changes are related to VNS efficacy for epilepsy.

NCT ID: NCT03937271 Withdrawn - Clinical trials for Rheumatoid Arthritis

Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome

Start date: April 1, 2019
Phase:
Study type: Observational

To explore the association among TCM pattern, TCM tongue diagnosis and TCM pulse diagnosis for Autoimmune disease and Dry eye syndrome

NCT ID: NCT03907540 Completed - Autoimmune Diseases Clinical Trials

Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

KD025-108
Start date: April 5, 2019
Phase: Phase 1
Study type: Interventional

Human, absorption, metabolism and excretion study of belumosudil (KD025)

NCT ID: NCT03901664 Completed - Autoimmune Diseases Clinical Trials

Lymphocyte Sub-populations and Auto Immune Diseases

SPLIT
Start date: February 1, 2018
Phase:
Study type: Observational

To determine if artificial intelligence allow to detect lymphocyte subpopulations specific of diseases (such as primary Sjogren' syndrome and systemic lupus erythematosus) among patients with suspicion of autoimmune diseases.